Antileukemic activity of lysophosphatidic acid acyltransferase-β inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib

Clinical Cancer Research

Volumn 12, Issue 21, 2006, Pages 6540-6546

  Rosée, Paul La ^a,b   Jia, Taiping ^a   Demehri, Shadmer ^a   Härtel, Nicolai ^b   De Vries, Peter ^c   Bonham, Lynn ^c   Hollenback, David ^c   Singer, Jack W ^c   Melo, Junia V ^d   Druker, Brian J ^a,e   Deininger, Michael W ^a,f  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Cell Therapeutics Inc   (United States)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CT 32228; IMATINIB; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE BETA INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CHRONIC MYELOID LEUKEMIA; COLONY FORMING UNIT GM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; DRUG MIXTURE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ACYLTRANSFERASES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEMATOPOIETIC STEM CELLS; HUMANS; HYDROCARBONS, HALOGENATED; IMMUNOBLOTTING; LEUKEMIA, MYELOID, CHRONIC; PHOSPHORYLATION; PIPERAZINES; PYRIMIDINES; TRIAZINES;

EID: 33751302125     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0140     Document Type: Article

References (34)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96: 3343-56.
2. Rowley JD. A new consistent chromosome abnormality in chronic myelogenous leukaemia detected by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-3.
3. Puil L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994;13:764-73.
4. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994;83:2038-44.
5. Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 1995;181:307-13.
6. Leevers SJ, Paterson HF, Marshall CJ. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 1994;369:411-4.
7. Stokoe D, Macdonald SG, Cadwallader K, Symons M, Hancock JF. Activation of Raf as a result of recruitment to the plasma membrane. Science 1994;264:1463-7.
8. Abraham E, Bursten S, Shenkar R, et al. Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice. J Exp Med 1995;181:569-75.
9. Bonham L, Leung DW, White T, et al. Lysophosphatidic acid acyltransferase-β: a novel target for induction of tumour cell apoptosis. Expert Opin Ther Targets 2003;7:643-61
10. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
11. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematological and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-9.
12. Marin D, Kaeda J, Szydlo R, et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia 2005;19:507-12.
13. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-25.
14. Thomas J, Wang L, Clark RE, Pimnohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739-45.
15. + cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005;105:2093-8.
16. Chu S, Holtz M, Gupta M, Bhatia R. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 2004;103:3167-74.
17. Coon M, Ball A, Pound J, et al. Inhibition of lysophosphatidic acid acyltransferase β disrupts proliferate and survival signals in normal cells and induces apoptosis of tumor cells. Mol Cancer Ther 2003;2:1067-78.
18. Hideshima T, Chauhan D, Hayashi T, et al. Antitumor activity of lysophosphatidic acid acyltransferase-β inhibitors, a novel class of agents, in multiple myeloma. Cancer Res 2003;63:8428-36.
19. Avanzi GC, Brizzi MF, Giannotti J, et al. M-07e human leukemic factor-dependent cell line provides a rapid and sensitive bioassay for the human cytokines GM-CSFand IL-3. J Cell Physiol 1990;145:458-64.
20. Greenberger JS, Sakakeeny MA, Humphries RK, Eaves CJ, Eckner RJ. Demonstration of permanent factor-dependent multipotential (erythroid/ neutrophil/basophil) hematopoietic progenitor cell lines. Proc Natl Acad Sci U S A 1983;80:2931-5.
21. Kubonishi I, Miyoshi I. Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. Int J Cell Cloning 1983;1: 105-17.
22. Seigneurin D, Champelovier P, Mouchiroud G, et al. Human chronic myeloid leukemic cell line with positive Philadelphia chromosome exhibits megakaryocytic and erythroid characteristics. Exp Hematol 1987;15: 822-32.
23. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975;45:321-34.
24. La Rosée P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 2002;62:7149-53.
25. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070-9.
26. La Rosée P, Johnson K, Corbin AS, et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood 2004; 103:208-15.
27. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
28. Brown AB. Hematology: principles and procedures. Philadelphia: Lea & Febiger: 1993. p. 101.
29. Jonuleit T, Peschel C, Schwab R, et al. Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors. Br J Haematol 1998;100:295-303.
30. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-6.
31. Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004;18:1321-31.
32. Kang YH, Yi MJ, Kim MJ, et al. Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen species-mediated poly(ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria. Cancer Res 2004;64:8960-7.
33. Law JC, Ritke MK, Yatowich JC, Leder GH, Ferrell RE. Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leuk Res 1993;17:1045-50.
34. 2 cell cycle arrest in p53- and p21-deficient cells by down-regulating p34cdc2 kinase activity. J Biol Chem 2005;280:7118-30.